A meta-analysis of breast cancer based on 48 randomized controlled trials found that Doxil showed a trend towards lower cardiotoxic and cardiac event rates compared to CDOX 24 – 26 .
← all excerpts
A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins.
1
—
—